Merck KGaASee all their emails

European Commission Approves Erbitux® (cetuximab) in Combination with Encorafenib and FOLFOX for First-Line Treatment of Metastatic Colorectal Cancer with BRAF V600E Mutation

A real announcement email from Merck KGaA. Captured July 14, 2026.

Make this email yours

Migma AI designs one like it with your logo, colors, and images.

European Commission Approves Erbitux® (cetuximab) in Combination with Encorafenib and FOLFOX for First-Line Treatment of Metastatic Colorectal Cancer with BRAF V600E Mutation email from Merck KGaA screenshot

Captured Announcement

Press release announcement regarding the European Commission approval of Erbitux for metastatic colorectal cancer treatment.

Header with logo, hero section with title and teaser image, followed by date/location, then a long-form text body with bullet points and detailed clinical trial data. Footer contains download links and company boilerplate.

Original email and brand assets belong to their respective owners. Design notes describe the creative, not campaign results.